Scancell Holdings PLC (GB:SCLP)
LSE:SCLP
Want to see GB:SCLP full AI Analyst Report?
Top Page
Scancell Holdings
(LSE:SCLP)
Select Model
Select Model
Rating:53Neutral
Price Target:
24.50 p
▲(151.28% Upside)
Action:Reiterated
Date:05/21/26
The score is capped primarily by weak financial strength (continued losses, cash burn, and negative equity) and valuation constraints from negative earnings. This is partially offset by strong earnings-call-driven clinical/regulatory momentum and a clear Phase III path, while technicals show an uptrend but also very overbought conditions that elevate short-term volatility risk.
Positive Factors
Strong Phase II efficacy signal (iSCIB1+ PFS 74%)
A 74% PFS at 16 months is a durable, clinically meaningful signal versus historical ipi/nivo benchmarks. This materially improves the program's probability of regulatory success, strengthens partner interest and licensing leverage, and underpins long-term commercial potential if confirmed in the Phase III registrational trial.
Negative Factors
Negative shareholder equity; modest asset base
Negative equity and a modest asset base weaken solvency optics and reduce financial flexibility. This structural balance-sheet weakness limits the company's ability to self‑fund a large registrational program, constrains borrowing capacity, and makes external financing terms or partnering outcomes more critical and potentially dilutive.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Phase II efficacy signal (iSCIB1+ PFS 74%)
A 74% PFS at 16 months is a durable, clinically meaningful signal versus historical ipi/nivo benchmarks. This materially improves the program's probability of regulatory success, strengthens partner interest and licensing leverage, and underpins long-term commercial potential if confirmed in the Phase III registrational trial.
Read all positive factors
Scancell Holdings (SCLP) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£254.26M
Dividend YieldN/A
Average Volume (3M)1.20M
Price to Earnings (P/E)―
Beta (1Y)<0.01
Revenue GrowthN/A
EPS Growth69.01%
CountryUK
Employees61
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,037,781,400
10 Day Avg. Volume991,653
30 Day Avg. Volume1,200,950
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)-27.20
Price to Sales (P/S)22.14
P/FCF Ratio-17.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)£1.20M
Scancell Holdings Business Overview & Revenue Model
Company Description
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include S...
How the Company Makes Money
Scancell’s business model is typical of an R&D-stage biotechnology company: it seeks to create value by advancing proprietary immunotherapy candidates through preclinical and clinical development and then monetizing those assets via partnerships a...
Scancell Holdings Earnings Call Summary
Earnings Call Date:Jan 29, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Oct 23, 2026
Earnings Call Sentiment Positive
The call conveyed strong clinical and regulatory progress—most notably the FDA IND clearance, compelling PFS data (74% at 16 months with a 24% delta), validated manufacturing and delivery, and multiple pipeline and partnered value drivers (including up to $630M in Genmab milestones). The primary negatives are financial (no revenue, interim net loss, and a cash runway into H2 2026) and the long, blinded Phase III timeline to a registrational readout in H2 2029 which necessitates near-term financing or milestone receipts. On balance, the positive clinical/regulatory milestones and clear commercial pathway outweigh the funding and timing headwinds.Positive Updates
Strong Efficacy Signal for iSCIB1+ (PFS)
iSCIB1+ demonstrated progression-free survival (PFS) of 74% at 16 months in Phase II data; reported a 24% delta versus historic/real-world benchmarks (comparison with ipilimumab+nivolumab median PFS ~11.5 months). Company also reported a ~16% improvement for prior SCIB1 on overall survival versus the comparator in their dataset, and noted similarity in order of magnitude to published Moderna 5‑year follow-up data.
Negative Updates
No Revenues Reported in Period
There were no revenues in the interim period; revenue upside depends on future partnered milestones (Genmab) and commercial success.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Efficacy Signal for iSCIB1+ (PFS)
iSCIB1+ demonstrated progression-free survival (PFS) of 74% at 16 months in Phase II data; reported a 24% delta versus historic/real-world benchmarks (comparison with ipilimumab+nivolumab median PFS ~11.5 months). Company also reported a ~16% improvement for prior SCIB1 on overall survival versus the comparator in their dataset, and noted similarity in order of magnitude to published Moderna 5‑year follow-up data.
Read all positive updates
Company Guidance
Management guided that iSCIB1+—which showed 74% PFS at 16 months (a ~24 percentage‑point delta versus historic ipi/nivo data with median PFS ≈11.5 months) from a Phase II translational dataset of ~140 patients—will move to a registrational Phase III two‑arm study of ~230 patients per arm (~460 total) with an adaptive design, IND cleared by the FDA, a surrogate primary endpoint (enabling accelerated approval), plans to pursue Fast Track and a Breakthrough designation (decision timeline ~2–3 months) and a target readout/commercialization window in H2 2029; financially, H1 (6 months to 31 Oct 2025) R&D spend was $6.2m, admin costs £2.7m, operating loss £8.9m, net loss £5.7m, cash £8.6m (including a £3.0m R&D tax credit) giving runway into H2 2026, while management pursues partnering/financing (including up to $630m of potential Genmab milestones), expects Modi‑1 data in H1, anticipates further Genmab/SC129 milestones this year, and notes patent protection to 2041 plus scalable manufacturing and a PharmaJet needle‑free delivery partnership.Scancell Holdings Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
18
Very Negative
Cash Flow
24
Negative
| Breakdown | TTM | Apr 2025 | Apr 2024 | Oct 2023 | Apr 2022 | Apr 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.71M | 4.71M | 0.00 | 5.27M | 0.00 | 0.00 |
| Gross Profit | 3.70M | 3.59M | -966.00K | 4.75M | -740.00K | -249.00K |
| EBITDA | -5.60M | -12.71M | -7.06M | -12.19M | -3.75M | -14.90M |
| Net Income | -5.51M | -12.27M | -5.86M | -11.94M | -2.06M | -15.48M |
Balance Sheet | ||||||
| Total Assets | 15.38M | 23.09M | 23.58M | 30.27M | 49.06M | 8.82M |
| Cash, Cash Equivalents and Short-Term Investments | 8.57M | 16.89M | 14.82M | 19.92M | 28.73M | 41.11M |
| Total Debt | 16.18M | 16.27M | 19.87M | 21.13M | 18.92M | 15.39M |
| Total Liabilities | 23.75M | 26.93M | 27.08M | 36.50M | 29.57M | 1.17M |
| Stockholders Equity | -8.37M | -3.83M | -3.50M | -6.23M | 18.11M | 19.48M |
Cash Flow | ||||||
| Free Cash Flow | -8.36M | -6.12M | -15.84M | -8.34M | -8.55M | -4.80M |
| Operating Cash Flow | -8.35M | -6.11M | -15.66M | -8.14M | -7.80M | -4.77M |
| Investing Cash Flow | -1.44M | -1.54M | 178.00K | 81.00K | -741.00K | -13.00K |
| Financing Cash Flow | 9.22M | 9.73M | 10.39M | -746.00K | 46.08M | 46.08M |
Scancell Holdings Technical Analysis
Positive
9.75
Price Trends
15.57
Positive
14.15
Positive
11.97
Positive
Market Momentum
2.59
Negative
65.67
Neutral
45.26
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:SCLP, the sentiment is Positive. The current price of 9.75 is below the 20-day moving average (MA) of 20.34, below the 50-day MA of 15.57, and below the 200-day MA of 11.97, indicating a bullish trend. The MACD of 2.59 indicates Negative momentum. The RSI at 65.67 is Neutral, neither overbought nor oversold. The STOCH value of 45.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:SCLP.
Scancell Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | £39.49M | -7.23 | -55.47% | ― | ― | 19.83% | |
53 Neutral | £254.26M | -44.99 | 90.29% | ― | ― | 69.01% | |
53 Neutral | £33.26M | -6.98 | -284.01% | ― | ― | -105.65% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | £24.92M | 37.53 | -197.54% | ― | 3.31% | 21.91% | |
43 Neutral | £78.20M | -4.85 | -116.21% | ― | 81.46% | -15.88% | |
37 Underperform | £77.76M | -6.32 | -506.43% | ― | 27.60% | 3.17% |
* Healthcare Sector Average
GB:SCLP
Scancell Holdings
23.90
13.90
139.00%
GB:SAR
Sareum Holdings
25.00
10.75
75.44%
GB:4BB
4basebio UK Societas
527.50
-582.50
-52.48%
GB:POLB
Poolbeg Pharma Ltd.
5.85
2.65
82.81%
GB:AREC
Arecor Therapeutics PLC
66.00
22.50
51.72%
GB:OBI
Ondine Biomedical, Inc.
15.00
6.50
76.47%
Scancell Holdings Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Scancell Wins FDA Fast Track for Melanoma Vaccine as Phase 2 Data Strengthen
Positive
Apr 28, 2026
Scancell Holdings has secured U.S. FDA Fast Track designation for its lead cancer vaccine candidate iSCIB1+ in advanced melanoma, underscoring the therapy’s potential to improve outcomes over current checkpoint inhibitor regimens. The compan...
Business Operations and StrategyExecutive/Board Changes
Scancell Taps Veteran Biotech Financier as Interim CFO Amid iSCIB1+ Push
Positive
Apr 2, 2026
Scancell Holdings, a UK-listed clinical-stage biotech focused on cancer immunotherapies, is advancing a portfolio that includes its lead DNA ImmunoBody candidate iSCIB1+ for melanoma, the Moditope-derived peptide vaccine Modi-1 in solid tumours, a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.